3rd Quarter - Report

NVG, LLC for ALEXION PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA - rare and orphan disease issues

LobbyistCovered position, as disclosed
LISA GERMAN FOSTER —
ANDREA LARUE New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Patent Quality Improvement Act of 2013 (S. 866, H.R. 2766), Patent Abuse Reduction Act of 2013 (S. 1013, H.R. 2639); The Innovation Act (HR 3309); Patent Transparency and Improvements Act of 2013 (S. 1720); General issues related to intellectual property and potential changes to the patent system

LobbyistCovered position, as disclosed
ANDREA LARUE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1720 (113th), H.R. 2639 (113th), H.R. 2766 (113th), S. 866 (113th), S. 1013 (113th), H.R. 3309 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.